Cargando…

Potential of resveratrol in the treatment of interstitial lung disease

Interstitial lung disease (ILD) is a heterogeneous group of diseases characterized by lung injury caused by lung fibroblast proliferation, interstitial inflammation, and fibrosis. Different cell signal transduction pathways are activated in response to various proinflammatory or fibrotic cytokines,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Rongxiu, Huang, Xinxiang, Yang, Yanting, Yang, Yang, Lin, Jinying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117935/ https://www.ncbi.nlm.nih.gov/pubmed/37089962 http://dx.doi.org/10.3389/fphar.2023.1139460

Ejemplares similares

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
por: Huo, Rongxiu, et al.
Publicado: (2023)

Mortality associated with Sjögren’s syndrome in the United States in the 1999–2020 period: A multiple cause-of-death study
por: Huo, Rongxiu, et al.
Publicado: (2023)

Systemic lupus erythematosus with diffuse alveolar hemorrhage
por: Huo, Rongxiu, et al.
Publicado: (2023)

Resveratrol: Potential Application in Sepsis
por: Li, Jiajia, et al.
Publicado: (2022)

Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease
por: Huo, Rongxiu, et al.
Publicado: (2022)

Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease
por: Rahman, Md. Habibur, et al.
Publicado: (2020)

Resveratrol: Multi-Targets Mechanism on Neurodegenerative Diseases Based on Network Pharmacology
por: Wang, Wenjun, et al.
Publicado: (2020)

Predictors of Mortality in Progressive Fibrosing Interstitial Lung Diseases
por: Chen, Xianqiu, et al.
Publicado: (2021)

Resveratrol—Potential Antibacterial Agent against Foodborne Pathogens
por: Ma, Dexter S. L., et al.
Publicado: (2018)

Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis
por: Xu, Linrui, et al.
Publicado: (2022)

Drug Repurposing Prediction and Validation From Clinical Big Data for the Effective Treatment of Interstitial Lung Disease
por: Siswanto, Soni, et al.
Publicado: (2021)

Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction
por: Yadav, Ekta, et al.
Publicado: (2022)

Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease
por: Li, Xiao, et al.
Publicado: (2023)

Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline
por: Nagy, Alexandra, et al.
Publicado: (2021)

Antioxidant and neuroprotective actions of resveratrol in cerebrovascular diseases
por: Wang, Qing, et al.
Publicado: (2022)

Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects
por: Nawa, Hideki, et al.
Publicado: (2021)

Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
por: Andrade, Stephanie, et al.
Publicado: (2018)

The therapeutic efficacy of resveratrol for acute lung injury—A meta−analysis of preclinical trials
por: Tang, Yin, et al.
Publicado: (2022)

Long-term clinical course and outcomes of patients with microscopic polyangiitis-associated interstitial lung disease
por: Kim, Min Jee, et al.
Publicado: (2023)

Prognostic Predictive Characteristics in Patients With Fibrosing Interstitial Lung Disease: A Retrospective Cohort Study
por: Wang, Yuanying, et al.
Publicado: (2022)

Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report
por: Conca, Walter, et al.
Publicado: (2020)

Resveratrol: French Paradox Revisited
por: Catalgol, Betul, et al.
Publicado: (2012)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
por: He, Xuan, et al.
Publicado: (2023)

Resveratrol activates CD8(+) T cells through IL-18 bystander activation in lung adenocarcinoma
por: Zhang, Wei, et al.
Publicado: (2022)

Low-Dose Resveratrol Inhibits RIPK3-Mediated Necroptosis and Delays the Onset of Age-Related Hearing Loss
por: Yang, Zeyin, et al.
Publicado: (2022)

Synergistic association of resveratrol and histone deacetylase inhibitors as treatment in amyotrophic lateral sclerosis
por: Parrella, Edoardo, et al.
Publicado: (2022)

Is Resveratrol a Cancer Immunomodulatory Molecule?
por: Trung, Ly Quoc, et al.
Publicado: (2018)

Treatment of myocardial interstitial fibrosis in pathological myocardial hypertrophy
por: Zhu, Fuyu, et al.
Publicado: (2022)

Resveratrol in Rodent Models of Parkinson’s Disease: A Systematic Review of Experimental Studies
por: Su, Cheng-Fu, et al.
Publicado: (2021)

Protective Effect of Resveratrol on Knee Osteoarthritis and its Molecular Mechanisms: A Recent Review in Preclinical and Clinical Trials
por: Yang, Shenglei, et al.
Publicado: (2022)

Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
por: Cotino-Nájera, Sandra, et al.
Publicado: (2023)

Role of resveratrol in inhibiting pathological cardiac remodeling
por: Fan, Shaowei, et al.
Publicado: (2022)

Resveratrol and Angiogenin-2 Combined With PEGDA/TCS Hydrogel for the Targeted Therapy of Hypoxic Bone Defects via Activation of the Autophagy Pathway
por: Fan, Dehui, et al.
Publicado: (2021)

Mechanisms of resveratrol against diabetic wound by network pharmacology and experimental validation
por: Youjun, Ding, et al.
Publicado: (2023)

Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Disease-Associated Interstitial Lung Disease:A Systematic Review and Meta-Analysis
por: Li, Yehui, et al.
Publicado: (2021)

Familial Interstitial Lung Disease Caused by Mutation of the STING1 Gene
por: Li, Jinying, et al.
Publicado: (2020)

World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) Core Set Development for Interstitial Lung Disease
por: Saketkoo, Lesley Ann, et al.
Publicado: (2022)

Resveratrol on the Metabolic Reprogramming in Liver: Implications for Advanced Atherosclerosis
por: Ma, Ying, et al.
Publicado: (2021)

The role of resveratrol on rheumatoid arthritis: From bench to bedside
por: Sheng, Shuyan, et al.
Publicado: (2022)

Pre-clinical Pharmacokinetic and Metabolomic Analyses of Isorhapontigenin, a Dietary Resveratrol Derivative
por: Dai, Yu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7cmhh7q14lu40mrlv7igf63jnr